News

Anti-obesity mkt heats up as Mounjaro's Kwikpen version gets India approval
Eli Lilly receives approval for Mounjaro in prefilled Kwikpen as competition intensifies in India's weight-loss drug market ...
StockStory.org on MSN8h
5 Revealing Analyst Questions From Eli Lilly’s Q1 Earnings Call
Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging ...
Fierce Pharma2h
Automation, robots and local talent guide the way at Lilly's new $2B-plus North Carolina injectables plant
After blueprinting an injectables facility in North Carolina in 2020, it didn’t take long for Eli Lilly to draw up designs ...
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow
Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...
Eli Lilly’s Obesity Pill Appears to Work as Well as Injected GLP-1s
New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...
inews.co.uk on MSN2d
No Mounjaro, GPs tell patients, unless you hit four criteria – and you’re very lucky
GPs and pharmacists have warned it will be impossible to meet soaring demand for weight-loss jabs following their rollout on ...
Fierce Pharma3d
Diabetes and obesity boom will propel Lilly, Novo to front of pharma sales pack by 2030: Evaluate
Fueled by a sustained boom in sales of its diabetes and obesity products, Eli Lilly will become the world’s top-seller of prescription drugs by 2030 and will hold the top rung by a wide margin. | ...